

August 6, 2025

## Q1FY26 Result Update

☑ Change in Estimates | ☑ Target | ■ Reco

### Change in Estimates

	Current		Previous	
	FY26E	FY27E	FY26E	FY27E
Rating	BUY		BUY	
Target Price	1,300		1,440	
Sales (Rs. m)	3,32,783	3,66,453	3,42,259	3,73,649
% Chng.	(2.8)	(1.9)		
EBITDA (Rs. m)	66,762	75,694	71,527	79,520
% Chng.	(6.7)	(4.8)		
EPS (Rs.)	63.1	76.2	70.3	80.6
% Chng.	(10.2)	(5.5)		

### Key Financials - Consolidated

Y/e Mar	FY24	FY25	FY26E	FY27E
Sales (Rs. m)	2,90,019	3,17,237	3,32,783	3,66,453
EBITDA (Rs. m)	58,430	66,054	66,762	75,694
Margin (%)	20.1	20.8	20.1	20.7
PAT (Rs. m)	35,567	34,859	36,632	44,231
EPS (Rs.)	60.7	60.0	63.1	76.2
Gr. (%)	88.4	(1.1)	5.1	20.7
DPS (Rs.)	6.0	3.0	7.0	7.0
Yield (%)	0.6	0.3	0.6	0.6
RoE (%)	12.5	11.2	10.7	11.7
RoCE (%)	12.7	12.9	11.8	12.7
EV/Sales (x)	2.2	2.0	1.8	1.6
EV/EBITDA (x)	10.8	9.4	9.2	7.9
PE (x)	17.8	18.0	17.1	14.2
P/BV (x)	2.1	1.9	1.7	1.6

### Key Data

ARBN.BO | ARBP IN

52-W High / Low	Rs.1,593 / Rs.994
Sensex / Nifty	80,710 / 24,650
Market Cap	Rs.627bn / \$ 7,139m
Shares Outstanding	581m
3M Avg. Daily Value	Rs.1388.61m

### Shareholding Pattern (%)

Promoter's	51.82
Foreign	14.38
Domestic Institution	26.93
Public & Others	6.87
Promoter Pledge (Rs bn)	-

### Stock Performance (%)

	1M	6M	12M
Absolute	(9.4)	(9.4)	(24.1)
Relative	(6.3)	(12.2)	(25.9)

### Param Desai

paramdesai@plindia.com | 91-22-66322259

### Kushal Shah

kushalshah@plindia.com | 91-22-66322490

## Weak US sales

### Quick Pointers:

- Reiterate margin guidance of 20-21%.
- Pen G yield improving, targeting EBITDA breakeven by Q3FY26E.

**Aurobindo Pharma's (ARBP) Q1FY26 EBITDA of Rs16.1bn (down 1% YoY) was 5% below our estimate led by lower US sales. Resultant our FY26 and FY27E EPS stands reduced by 5-10%. The company has maintained its 20-21% OPM guidance for FY26E despite gRevlimid sales loss. We expect margins and revenues to improve from H2FY26/FY27 with ramp up in PenG facility, Vizag pant commercialization and launches in US. We believe ARBP has multiple growth drivers in place with investments in vaccines, injectables, biosimilars and PLI which are expected to be reflected from FY26. Given attractive valuations (8x EV/EBITDA / 14x P/E on FY27E), we maintain our "Buy" with revised TP of Rs1,300/share; valuing at 17x (18x earlier) FY27E EPS.**

- Lower US sales led to revenue miss:** Overall Revenue came in at Rs79bn, up 4% YoY, (we est Rs 82bn). US revenues came lower at \$408mn, down 13% QoQ and 4% YoY (we est \$450mn). Mgmt cited lower gRevlimid sales and seasonal dynamics to such decline. EU sales were up 18% YoY while RoW business was up 9% YoY. ARV formulations came in higher - up 55% YoY. API sales declined 16% YoY.
- Margins remain healthy despite lower gRevlimid sales:** Gross margins remain healthy at 58.8% (largely flat QoQ) despite \$60mn lower gRevlimid sales. R&D spent stood at Rs 3.7bn (4.7% of revenue), up 8% YoY. Other expenses ex R&D were down 2% YoY. Resultant EBITDA margins came in at 20.4% down 100bps QoQ. EBITDA came at Rs16.1bn (down 1% YoY), (we est Rs 16.8bn). Tax rate higher at 32%. Resultant PAT at Rs8.2bn; 9% below our est. EPS at Rs 14/share.

## Key Conference Call Takeaways

- US:** Revenues were impacted due to, loss of Rs 1.5bn YoY and Rs 5.5bn QoQ sales in gRevlimid. No major gRevlimid sales expected ahead, as most of the allocated inventory has been exhausted. Further oral solid sales were affected by destocking ahead of anticipated tariff changes. 15 new products were launched in the US during Q1. 4 ANDAs were filed, and 14 approvals were received during the quarter. US injectables business grew 11% QoQ.
- Dayton facility** (\$70 mn investment) awaits regulatory approval; commercial production expected in Q2-Q3 FY26. Biologics CMO- \$13mn spent with further \$100mn to be spent by March 2027
- Europe:** Strong and sustained growth continued across all major markets an don track to cross Eur 1bn revenues in FY26. Margins are improving towards 20% range, supported by increased in-house manufacturing. Added 2 new lines for oncology products to meet the rising demand.

- **Ems & ARVs:** Supported by strong performance in key markets like Brazil and Canada. **ARV:** Growth was driven by strong volume uptick and new tender wins.
- **API:** Revenue was impacted by pricing pressure, adverse business mix, and geopolitical challenges. Seasonal weakness in demand also affected volumes.
- **PenG plant:** Commercial production began on July 1. Yields improving; contribution to financials expected from Q3 FY26. Targeting EBITDA breakeven by Q3FY26. Production target set at 7,000–8,000 tons with PLI income estimated at Rs 1.5bn in FY26.
- **Biosimilars:** Received 4 European approvals: 3 from EMA and 1 from MHRA. Commercial revenues expected to begin from Q3–Q4 FY26. Focus remains on building a robust supply chain and finalizing partnerships in markets where ARBP is not present.
- **China:** \$145 mn invested with capacity for 2 bn units. Invoicing started in Q1 FY26; breakeven expected by Q3 FY26.
- **Vizag:** Plans to file 20+ products for the US and Europe over the next two years. On Eugia-3 have invited USFDA for reinspection.
- **Lannett Acquisition:** Portfolio includes 70+ active products, primarily in controlled substances, with a strong focus on non-opioid ADHD medications that are stable and in short supply. Lannett also has a CMO business, with existing contracts across multiple countries. ARBP expects to benefit from synergies in business development, in-licensing, and CMO capabilities. The business currently operates at ~30% gross margin with EBITDA margin of 15%. Capacity utilization stands at ~40%. Management does not foresee significant portfolio overlap that could hinder FTC clearance.
- **Guidance-** Maintained its 20-21% OPM for FY26 despite gRevlimid sales loss. Volume expansion continued product launches, and a stable pricing environment especially in the US and Europe. Ramping up of commercial operations at new manufacturing sites would further support revenue growth and margin improvement in the upcoming quarters
- **Other:** Gross debt reduced to \$884 mn, down from \$930 mn in the previous quarter. Finance cost declined to 4.9%, from 5.5% QoQ. Net cash at \$140 mn in Q1FY26. FCF stood at \$98 mn in Q1; the company is targeting \$100 million FCF per quarter, supported by improved working capital and lower capex. R&D spend was towards with focus on complex generics and specialty therapies. Net CapEx for the quarter was \$73 mn. Company is prepared for US tariff shifts; higher costs expected to be offset by better pricing.

**Exhibit 1: 1QFY26 Result Overview (Rs m): EBITDA miss led by lower US revenues**

Y/e March	1QFY26	1QFY25	YoY gr. (%)	1QFY26E	% Var	4QFY25	QoQ gr. (%)	FY26E	FY25	YoY gr. (%)
<b>Net Sales</b>	<b>78,681</b>	<b>75,670</b>	<b>4.0</b>	<b>81,981</b>	<b>(4.0)</b>	<b>83,821</b>	<b>(6.1)</b>	<b>3,32,783</b>	<b>3,17,237</b>	<b>4.9</b>
Raw Material	32,392	30,727	5.4	33,858	(4.3)	34,279	(5.5)	1,37,368	1,30,262	5.5
% of Net Sales	41.2	40.6		41.3		40.9		41.3	41.1	
Personnel Cost	12,288	10,720	14.6	11,791	4.2	11,626	5.7	49,232	44,756	10.0
% of Net Sales	15.6	14.2		14.4		13.9		14.8	14.1	
Others	17,967	18,028	(0.3)	19,470	(7.7)	19,997	(10.2)	79,421	76,164	4.3
% of Net Sales	22.8	23.8		23.7		23.9		23.9	24.0	
Total Expenditure	62,647	59,475	5.3	65,120	(3.8)	65,902	(4.9)	2,66,021	2,51,183	5.9
<b>EBITDA</b>	<b>16,034</b>	<b>16,196</b>	<b>(1.0)</b>	<b>16,861</b>	<b>(4.9)</b>	<b>17,919</b>	<b>(10.5)</b>	<b>66,762</b>	<b>66,054</b>	<b>1.1</b>
Margin (%)	20.4	21.4		20.6		21.4		20.1	20.8	
Depreciation	4,057	4,042	0.4	4,400	(7.8)	4,444	(8.7)	17,154	16,494	4.0
<b>EBIT</b>	<b>11,977</b>	<b>12,154</b>	<b>(1.5)</b>	<b>12,461</b>	<b>(3.9)</b>	<b>13,475</b>	<b>(11.1)</b>	<b>49,608</b>	<b>49,560</b>	<b>0.1</b>
Other Income	1,053	2,209	(52.3)	1,300	(19.0)	1,348	(21.9)	6,000	6,219	(3.5)
Forex gain / (loss)	-	-	#DIV/O!	-		(116)		-	(227)	
Interest	978	1,110	(12.0)	1,120	(12.7)	1,150	(15.0)	3,600	4,572	(21.3)
<b>PBT</b>	<b>12,053</b>	<b>13,253</b>	<b>(9.1)</b>	<b>12,641</b>	<b>(4.7)</b>	<b>13,673</b>	<b>(11.8)</b>	<b>52,008</b>	<b>50,979</b>	<b>2.0</b>
Extra-Ord. Inc./Exps.	-	-		-		-		-	-	
Total Taxes	3,826	4,057	(5.7)	3,540	8.1	4,323	(11.5)	15,082	15,827	(4.7)
<b>ETR (%)</b>	<b>31.7</b>	<b>30.6</b>		<b>28.0</b>		<b>31.6</b>		<b>29.0</b>	<b>31.0</b>	
Minority interest	25	(14)		(20)		(315)		(294)	(294)	
<b>Reported PAT</b>	<b>8,252</b>	<b>9,182</b>	<b>(10.1)</b>	<b>9,082</b>	<b>(9.1)</b>	<b>9,035</b>	<b>(8.7)</b>	<b>36,632</b>	<b>34,858</b>	<b>5.1</b>


Source: Company, PL

**Exhibit 2: Improved EU performance YoY**

Major sources of revenues	1QFY26	1QFY25	YoY gr. (%)	4QFY25	QoQ gr. (%)	FY26E	FY25	YoY gr. (%)
<b>Formulations</b>	<b>69,530</b>	<b>64,750</b>	<b>7.4</b>	<b>73,130</b>	<b>(4.9)</b>	<b>2,85,296</b>	<b>2,74,007</b>	<b>4.1</b>
% of Net Sales	88.4	85.6		87.2		85.7	86.4	
USA	34,880	35,550	(1.9)	40,720	(14.3)	1,47,644	1,48,290	(0.4)
% of Net Sales	44.3	47.0		48.6		44.4	46.7	
Europe & Emerging Markets	31,100	26,910	15.6	29,330	6.0	1,25,669	1,15,347	8.9
% of Net Sales	39.5	35.6		35.0		37.8	36.4	
ARV	3,550	2,290	55.0	3,080	15.3	11,982	10,370	15.5
% of Net Sales	4.5	3.0		3.7		3.6	3.3	
<b>API</b>	<b>9,160</b>	<b>10,920</b>	<b>(16.1)</b>	<b>10,690</b>	<b>(14.3)</b>	<b>47,487</b>	<b>43,230</b>	<b>9.8</b>
% of Net Sales	11.6	14.4		12.8		14.3	13.6	


Source: Company, PL

**Exhibit 3: Delivered single digit growth YoY**




Source: Company, PL

**Exhibit 4: Lower gRevlimid sales impacted US business QoQ**




Source: Company, PL

**Exhibit 5: EU performance led by key markets YoY**




Source: Company, PL

**Exhibit 6: API Price pressure persists YoY**



Source: Company, PL

**Exhibit 7: Margins stable at ~20.4%**



Source: Company, PL



## Financials

### Income Statement (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
<b>Net Revenues</b>	<b>2,90,019</b>	<b>3,17,237</b>	<b>3,32,783</b>	<b>3,66,453</b>
YoY gr. (%)	16.7	9.4	4.9	10.1
Cost of Goods Sold	1,26,029	1,30,262	1,37,368	1,52,790
Gross Profit	1,63,990	1,86,975	1,95,414	2,13,663
Margin (%)	56.5	58.9	58.7	58.3
Employee Cost	39,229	44,756	49,232	53,663
Other Expenses	66,330	76,164	79,421	84,306
<b>EBITDA</b>	<b>58,430</b>	<b>66,054</b>	<b>66,762</b>	<b>75,694</b>
YoY gr. (%)	57.1	13.0	1.1	13.4
Margin (%)	20.1	20.8	20.1	20.7
Depreciation and Amortization	15,217	16,494	17,154	18,355
<b>EBIT</b>	<b>43,214</b>	<b>49,560</b>	<b>49,608</b>	<b>57,339</b>
Margin (%)	14.9	15.6	14.9	15.6
Net Interest	2,897	4,572	3,600	3,000
Other Income	5,574	5,992	6,000	7,500
<b>Profit Before Tax</b>	<b>45,890</b>	<b>50,980</b>	<b>52,008</b>	<b>61,839</b>
Margin (%)	15.8	16.1	15.6	16.9
Total Tax	12,110	15,827	15,082	17,315
Effective tax rate (%)	26.4	31.0	29.0	28.0
<b>Profit after tax</b>	<b>33,780</b>	<b>35,152</b>	<b>36,925</b>	<b>44,524</b>
Minority interest	132	294	294	294
Share Profit from Associate	-	-	-	-
<b>Adjusted PAT</b>	<b>35,567</b>	<b>34,859</b>	<b>36,632</b>	<b>44,231</b>
YoY gr. (%)	88.4	(2.0)	5.1	20.7
Margin (%)	12.3	11.0	11.0	12.1
Extra Ord. Income / (Exp)	-	-	-	-
<b>Reported PAT</b>	<b>35,567</b>	<b>34,859</b>	<b>36,632</b>	<b>44,231</b>
YoY gr. (%)	88.4	(2.0)	5.1	20.7
Margin (%)	12.3	11.0	11.0	12.1
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	35,567	34,859	36,632	44,231
<b>Equity Shares O/s (m)</b>	<b>586</b>	<b>581</b>	<b>581</b>	<b>581</b>
<b>EPS (Rs)</b>	<b>60.7</b>	<b>60.0</b>	<b>63.1</b>	<b>76.2</b>

Source: Company Data, PL Research

### Balance Sheet Abstract (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
<b>Non-Current Assets</b>				
<b>Gross Block</b>	<b>2,35,597</b>	<b>2,60,152</b>	<b>2,90,152</b>	<b>3,20,152</b>
Tangibles	2,35,597	2,60,152	2,90,152	3,20,152
Intangibles	-	-	-	-
<b>Acc: Dep / Amortization</b>	<b>79,376</b>	<b>95,870</b>	<b>1,13,024</b>	<b>1,31,379</b>
Tangibles	79,376	95,870	1,13,024	1,31,379
Intangibles	-	-	-	-
<b>Net fixed assets</b>	<b>1,56,221</b>	<b>1,64,282</b>	<b>1,77,128</b>	<b>1,88,773</b>
Tangibles	1,56,221	1,64,282	1,77,128	1,88,773
Intangibles	-	-	-	-
Capital Work In Progress	27,394	32,660	32,660	32,660
Goodwill	-	-	-	-
Non-Current Investments	3,722	2,517	2,517	2,517
Net Deferred tax assets	8,561	9,887	9,887	9,887
Other Non-Current Assets	-	-	-	-
<b>Current Assets</b>				
Investments	-	-	-	-
Inventories	98,082	1,05,437	1,10,604	1,21,795
Trade receivables	48,167	57,459	59,449	65,464
Cash & Bank Balance	62,783	82,355	89,198	95,305
Other Current Assets	-	-	-	-
<b>Total Assets</b>	<b>4,34,252</b>	<b>4,84,920</b>	<b>5,15,787</b>	<b>5,55,168</b>
<b>Equity</b>				
Equity Share Capital	586	581	581	581
Other Equity	2,97,842	3,25,952	3,57,827	3,97,301
<b>Total Networth</b>	<b>2,98,428</b>	<b>3,26,533</b>	<b>3,58,408</b>	<b>3,97,882</b>
<b>Non-Current Liabilities</b>				
Long Term borrowings	41,803	63,800	58,800	53,801
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
<b>Current Liabilities</b>				
ST Debt / Current of LT Debt	21,349	15,617	15,617	15,617
Trade payables	44,542	41,889	45,587	50,199
Other current liabilities	36,611	47,032	47,032	47,032
<b>Total Equity &amp; Liabilities</b>	<b>4,34,252</b>	<b>4,84,920</b>	<b>5,15,787</b>	<b>5,55,168</b>

Source: Company Data, PL Research

**Cash Flow (Rs m)**

Y/e Mar	FY24	FY25	FY26E	FY27E
PBT	45,890	50,980	52,008	61,839
Add. Depreciation	15,217	16,494	17,154	18,355
Add. Interest	2,897	4,572	3,600	3,000
Less Financial Other Income	5,574	5,992	6,000	7,500
Add. Other	(5,242)	-	-	-
Op. profit before WC changes	58,762	72,046	72,762	83,194
Net Changes-WC	(16,751)	(15,534)	(7,480)	(17,016)
Direct tax	(17,666)	(17,314)	(15,082)	(17,315)
<b>Net cash from Op. activities</b>	<b>24,345</b>	<b>39,199</b>	<b>50,200</b>	<b>48,863</b>
Capital expenditures	(35,851)	(25,540)	(30,000)	(30,000)
Interest / Dividend Income	-	-	-	-
Others	-	-	-	-
<b>Net Cash from Invst. activities</b>	<b>(35,851)</b>	<b>(25,540)</b>	<b>(30,000)</b>	<b>(30,000)</b>
Issue of share cap. / premium	-	(9,302)	-	-
Debt changes	14,613	16,037	(5,000)	(4,999)
Dividend paid	(2,636)	10	(4,757)	(4,757)
Interest paid	302	730	(3,600)	(3,000)
Others	1,168	(1,562)	0	-
<b>Net cash from Fin. activities</b>	<b>13,447</b>	<b>5,912</b>	<b>(13,357)</b>	<b>(12,756)</b>
<b>Net change in cash</b>	<b>1,941</b>	<b>19,572</b>	<b>6,843</b>	<b>6,107</b>
Free Cash Flow	(11,270)	14,003	20,200	18,863

Source: Company Data, PL Research

**Quarterly Financials (Rs m)**

Y/e Mar	Q2FY25	Q3FY25	Q4FY25	Q1FY26
<b>Net Revenue</b>	<b>77,960</b>	<b>79,785</b>	<b>83,821</b>	<b>78,681</b>
YoY gr. (%)	8.0	8.5	10.6	4.0
Raw Material Expenses	32,103	33,154	34,279	32,392
Gross Profit	45,857	46,631	49,542	46,289
Margin (%)	58.8	58.4	59.1	58.8
<b>EBITDA</b>	<b>15,661</b>	<b>16,278</b>	<b>17,919</b>	<b>16,034</b>
YoY gr. (%)	11.6	1.7	6.2	(1.0)
Margin (%)	20.1	20.4	21.4	20.4
Depreciation / Depletion	3,823	4,185	4,444	4,057
<b>EBIT</b>	<b>11,838</b>	<b>12,093</b>	<b>13,475</b>	<b>11,977</b>
Margin (%)	15.2	15.2	16.1	15.2
Net Interest	1,127	1,185	1,150	978
Other Income	1,068	2,071	1,116	1,053
<b>Profit before Tax</b>	<b>11,779</b>	<b>12,979</b>	<b>13,441</b>	<b>12,053</b>
Margin (%)	15.1	16.3	16.0	15.3
Total Tax	3,905	3,543	4,323	3,826
Effective tax rate (%)	33.2	27.3	32.2	31.7
<b>Profit after Tax</b>	<b>7,874</b>	<b>9,436</b>	<b>9,118</b>	<b>8,227</b>
Minority interest	3	18	(315)	25
Share Profit from Associates	-	-	-	-
<b>Adjusted PAT</b>	<b>8,169</b>	<b>8,458</b>	<b>9,035</b>	<b>8,252</b>
YoY gr. (%)	8.5	(10.0)	(21.6)	(10.1)
Margin (%)	10.5	10.6	10.8	10.5
Extra Ord. Income / (Exp)	-	-	-	-
<b>Reported PAT</b>	<b>8,169</b>	<b>8,458</b>	<b>9,035</b>	<b>8,252</b>
YoY gr. (%)	8.5	(10.0)	(21.6)	(10.1)
Margin (%)	10.5	10.6	10.8	10.5
Other Comprehensive Income	-	-	-	-
<b>Total Comprehensive Income</b>	<b>8,169</b>	<b>8,458</b>	<b>9,035</b>	<b>8,252</b>
Avg. Shares O/s (m)	-	-	-	-
<b>EPS (Rs)</b>	<b>13.9</b>	<b>14.4</b>	<b>16.5</b>	<b>14.0</b>

Source: Company Data, PL Research

**Key Financial Metrics**

Y/e Mar	FY24	FY25	FY26E	FY27E
<b>Per Share(Rs)</b>				
EPS	60.7	60.0	63.1	76.2
CEPS	86.7	88.4	92.6	107.8
BVPS	509.3	562.2	617.1	685.1
FCF	(19.2)	24.1	34.8	32.5
DPS	6.0	3.0	7.0	7.0
<b>Return Ratio(%)</b>				
RoCE	12.7	12.9	11.8	12.7
ROIC	11.6	12.3	11.6	12.5
RoE	12.5	11.2	10.7	11.7
<b>Balance Sheet</b>				
Net Debt : Equity (x)	-	0.0	0.0	(0.1)
Net Working Capital (Days)	128	139	137	137
<b>Valuation(x)</b>				
PER	17.8	18.0	17.1	14.2
P/B	2.1	1.9	1.7	1.6
P/CEPS	12.5	12.2	11.7	10.0
EV/EBITDA	10.8	9.4	9.2	7.9
EV/Sales	2.2	2.0	1.8	1.6
Dividend Yield (%)	0.6	0.3	0.6	0.6


Source: Company Data, PL Research

**Key Operating Metrics**

Y/e Mar	FY24	FY25	FY26E	FY27E
US Formulations	1,42,090	1,48,290	1,47,644	1,61,740
EU & ROW	96,830	1,15,347	1,25,669	1,37,854
ARV formulations	8,680	10,370	11,982	12,940
APIs	42,410	43,230	43,230	46,256

Source: Company Data, PL Research

**Price Chart**



**Recommendation History**

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	08-Jul-25	BUY	1,440	1,185
2	27-May-25	BUY	1,440	1,191
3	08-Apr-25	BUY	1,510	1,097
4	10-Feb-25	BUY	1,510	1,192
5	08-Jan-25	Accumulate	1,475	1,298
6	12-Nov-24	Accumulate	1,475	1,286
7	07-Oct-24	Accumulate	1,525	1,466
8	13-Aug-24	Accumulate	1,525	1,462

**Analyst Coverage Universe**

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Apollo Hospitals Enterprise	BUY	8,350	7,616
2	Aster DM Healthcare	BUY	700	605
3	Aurobindo Pharma	BUY	1,440	1,185
4	Cipla	BUY	1,730	1,533
5	Divi's Laboratories	Accumulate	6,800	6,889
6	Dr. Reddy's Laboratories	Reduce	1,270	1,247
7	Eris Lifesciences	BUY	1,740	1,734
8	Fortis Healthcare	BUY	785	806
9	HealthCare Global Enterprises	BUY	620	560
10	Indoco Remedies	Hold	325	322
11	Ipca Laboratories	Accumulate	1,525	1,456
12	J.B. Chemicals & Pharmaceuticals	BUY	2,030	1,778
13	Jupiter Life Line Hospitals	BUY	1,720	1,451
14	Krishna Institute of Medical Sciences	BUY	725	695
15	Lupin	BUY	2,400	1,979
16	Max Healthcare Institute	BUY	1,300	1,300
17	Narayana Hrudayalaya	BUY	2,000	1,830
18	Rainbow Children's Medicare	BUY	1,725	1,541
19	Sun Pharmaceutical Industries	BUY	1,875	1,707
20	Sunteck Realty	BUY	650	427
21	Torrent Pharmaceuticals	Accumulate	4,000	3,623
22	Zydus Lifesciences	Accumulate	970	999

**PL's Recommendation Nomenclature (Absolute Performance)**

<b>Buy</b>	: > 15%
<b>Accumulate</b>	: 5% to 15%
<b>Hold</b>	: +5% to -5%
<b>Reduce</b>	: -5% to -15%
<b>Sell</b>	: < -15%
<b>Not Rated (NR)</b>	: No specific call on the stock
<b>Under Review (UR)</b>	: Rating likely to change shortly



## **ANALYST CERTIFICATION**

### **(Indian Clients)**

We/I, Mr. Param Desai- MBA Finance, Mr. Kushal Shah- CFP, Passed CFA Level I Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### **(US Clients)**

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

## **DISCLAIMER**

### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at [www.plindia.com](http://www.plindia.com).

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai- MBA Finance, Mr. Kushal Shah- CFP, Passed CFA Level I Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

### **US Clients**

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

**Prabhudas Lilladher Pvt. Ltd.**

**3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209**

**[www.plindia.com](http://www.plindia.com)**